arXiv:2501. 12434v3 Announce Type: replace-cross Abstract: Motivation: Retrosynthesis plays a crucial role in organic synthesis and drug discovery, focusing on identifying a set of reactants capable of synthesizing a target product molecule.
By Jiaxi Zhuang, Yu Zhang, Ying Qian, Aimin Zhou
The paper introduces Equivariant-Free Transformer-Autoencoded Latent Flow Matching (EF‑TALFM), a two‑stage generative framework that uses a single fixed‑dimensional latent vector to produce variable‑size 3D molecules. The first stage samples the latent vector via flow matching, and the second stage employs an autoregressive Transformer decoder that determines molecule size while generating atom types, coordinates, and chemical states. EF‑TALFM outperforms prior methods on the PCQM4Mv2 benchmark, achieving higher uniqueness, novelty, and computational throughput, and its internal ranking improves the hit rate for target HOMO–LUMO gaps while maintaining novelty.
arXiv:2609.08333v1 Announce Type: cross
Abstract: In molecular discovery, molecule size is coupled to composition, structure, and other target properties. Yet most 3D generators require molecule size...
By Weichi Yao, Cameron Gruich, Bryan R. Goldsmith, Yixin Wang
WEECFP-SuRGE introduces a position‑aware substructure encoding method that combines tokenized hierarchical Morgan fingerprints with graph‑distance‑dependent rotations applied at the input and within transformer self‑attention. The approach captures local chemistry, long‑range interactions, and molecular topology without requiring external pretraining or 3‑D conformer generation. Benchmarks on MoleculeNet and the Therapeutic Data Commons ADMET datasets show competitive performance, and a reconstruction procedure correctly identifies constitutional isomers for 92.6% of a 4,200‑molecule library.
By Robert Epps
arXiv:2607. 12380v1 Announce Type: new Abstract: Small molecules, crystals, and proteins all reduce to atoms in 3D space, yet their generative pipelines remain fragmented across domains, each with its Small molecules, crystals, and proteins all reduce to atoms in 3D space, yet their generative pipelines remain fragmented across domains, each with its own graph, equivariant, or frame-based architecture.
By Yuxuan Ren, Fan Yang, Jianhua Yao, Yatao Bian
arXiv:2606. 25006v1 Announce Type: new Abstract: Target-specific peptide design requires sequence and structure co-design under full atom geometric constraints.
By Rui Jiao, Xiangzhe Kong, Yinjun Jia, Yijia Zhang, Ziyi Yang, Yang Liu, Jianzhu Ma
arXiv:2607. 01105v1 Announce Type: new Abstract: We present SynLaD, a latent diffusion framework for small-molecule generation that unifies ligand-based drug design objectives (what to make) with synthetic accessibility (how to make it).
By Miruna Cretu, John Bradshaw, Patricia Suriana, Saeed Saremi, Omar Mahmood, Kirill Shmilovich, Kangway Chuang, Vishnu Sresht, Colin Grambow
arXiv:2607. 09277v1 Announce Type: new Abstract: Three-dimensional (3D) molecule generation has been dominated by diffusion models, which achieve strong generation quality but typically require the molecular size to be specified a priori.
By Federico Ottomano, Gaopeng Ren, Yingzhen Li, Kim E. Jelfs, Alex M. Ganose
Target-specific peptide design requires sequence and structure co-design under full atom geometric constraints. Latent generative frameworks offer an effective route for this problem by compressing fine grained atomic structures into block level latent representations and performing conditional generation in a compact latent space.
arXiv:2607. 20551v1 Announce Type: cross Abstract: Effective molecular representation learning is crucial for accurate molecular property prediction.
By Tianming Han, Li Zhang, Qi Zhao
arXiv:2608.31009v1 Announce Type: new
Abstract: Structure-based drug design (SBDD) requires ligands that satisfy both 3D target affinity and 1D chemical validity. Existing controllable generation met...
By Tianyu Gao, Zhikai Su, Jiashu Li, Wenjun Gao, Zichuan Ying, Zhe Zhao, Fei Zhang, Ye Wei
arXiv:2607. 18144v1 Announce Type: cross Abstract: Structure-based drug design (SBDD) leverages the 3D structure of protein targets, often complemented by other spatial constraints, to generate candidate binding molecules.
By Thomas MacDougall, Maksim Kuznetsov, Roman Schutski, Rim Shayakhmetov, Maxim Malkov, Vladimir Aladinskiy, Alex Aliper, Alex Zhavoronkov